

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9480289/brigette-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

192 papers	11,051 citations	50 h-index	102 g-index
228 ext. papers	13,152 ext. citations	5.1 avg, IF	5.76 L-index

#	Paper	IF	Citations
192	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016 , 27, 1386-422	10.3	1683
191	A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1532-8	9.7	490
190	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 619-29	21.7	428
189	Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3356-64	2.2	410
188	Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 242-9	2.2	405
187	Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 536-9	9.7	371
186	Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. <i>New England Journal of Medicine</i> , 2017 , 377, 513-522	59.2	338
185	Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 1614-9	9.7	315
184	Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5414-8	2.2	285
183	Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 18761-8	11.5	267
182	Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3568-76	2.2	233
181	New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. <i>Journal of Clinical Oncology</i> , 2009 , 27, 446-52	2.2	205
180	Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). <i>Journal of Clinical Oncology</i> , 2018 , 36, 1412-1418	2.2	185
179	Exome and genome sequencing of nasopharynx cancer identifies NF- κ B pathway activating mutations. <i>Nature Communications</i> , 2017 , 8, 14121	17.4	163
178	Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2211-7	2.2	146
177	Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study. <i>Head and Neck</i> , 2003 , 25, 864-72	4.2	146
176	Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. <i>Annals of Oncology</i> , 2014 , 25, 1204-8	10.3	138

175	Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. <i>Annals of Oncology</i> , 2004 , 15, 1661-6	10.3	132
174	Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. <i>Cancer</i> , 2003 , 98, 288-91	6.4	129
173	Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. <i>Cancer Research</i> , 2013 , 73, 1676-88	10.1	127
172	A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. <i>Investigational New Drugs</i> , 2008 , 26, 169-73	4.3	123
171	The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. <i>International Journal of Gynecological Cancer</i> , 2004 , 14, 650-8	3.5	120
170	Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2760-76	2.2	115
169	Population-based differences in treatment outcome following anticancer drug therapies. <i>Lancet Oncology</i> , 2010 , 11, 75-84	21.7	110
168	Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3053-60	2.2	103
167	Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. <i>Cancer</i> , 2005 , 103, 22-31	6.4	100
166	Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. <i>Cancer Science</i> , 2008 , 99, 1311-8	6.9	96
165	A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. <i>Annals of Oncology</i> , 2012 , 23, 1287-1292	10.3	91
164	Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. <i>Oncogene</i> , 2007 , 26, 7490-8	9.2	91
163	Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2018 , JCO2018777847	2.2	90
162	The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. <i>European Journal of Cancer</i> , 2009 , 45, 1146-1152	7.5	86
161	Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 66, 714-20	4	84
160	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. <i>Genome Research</i> , 2019 , 29, 418-427	9.7	81
159	Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials. <i>Clinical Cancer Research</i> , 2018 , 24, 1824-1833	12.9	78
158	Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. <i>Annals of Oncology</i> , 2011 , 22, 1280-1287	10.3	77

157	Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E5115-E5124	11.5	75
156	Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. <i>Cancer</i> , 2002 , 95, 2516-23	6.4	73
155	Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. <i>BMC Cancer</i> , 2015 , 15, 395	4.8	72
154	Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2012 , 104, 300-4	5.3	68
153	The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. <i>British Journal of Radiology</i> , 2008 , 81, 291-8	3.4	67
152	A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 59-64	3.5	67
151	Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26, 340-7	4	64
150	STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. <i>International Journal of Cancer</i> , 2009 , 125, 1884-93	7.5	58
149	Dynamic contrast enhancement magnetic resonance imaging (DCE-MRI) for differential diagnosis in head and neck cancers. <i>European Journal of Radiology</i> , 2012 , 81, 784-8	4.7	56
148	Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. <i>Clinical Cancer Research</i> , 2009 , 15, 1005-12	12.9	56
147	Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer. <i>Hematology/Oncology Clinics of North America</i> , 2008 , 22, 1267-78, x	3.1	56
146	The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. <i>Investigational New Drugs</i> , 2010 , 28, 413-20	4.3	55
145	The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation. <i>Molecular Cancer Research</i> , 2014 , 12, 228-38	6.6	53
144	Radiotherapy for nasopharyngeal carcinoma--transition from two-dimensional to three-dimensional methods. <i>Radiotherapy and Oncology</i> , 2004 , 73, 163-72	5.3	53
143	The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. <i>Investigational New Drugs</i> , 2010 , 28, 107-14	4.3	52
142	Advanced proteomic technologies for cancer biomarker discovery. <i>Expert Review of Proteomics</i> , 2009 , 6, 123-34	4.2	49
141	Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. <i>Medical Oncology</i> , 2005 , 22, 303-12	3.7	49
140	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. <i>Clinical Chemistry</i> , 2018 , 64, 1239-1249	5.5	47

139	Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. <i>Cancer Biology and Therapy</i> , 2014 , 15, 768-76	4.6	47
138	Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms. <i>Annals of Oncology</i> , 2009 , 20, 1854-9	10.3	47
137	Predictive factors for overall quality of life in patients with advanced cancer. <i>Supportive Care in Cancer</i> , 2013 , 21, 1709-16	3.9	46
136	Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. <i>Cancer Letters</i> , 2007 , 253, 74-88	9.9	46
135	Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer -- a retrospective review of Chinese patients and comparison with an historic Western series. <i>Radiotherapy and Oncology</i> , 2002 , 62, 185-9	5.3	44
134	A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. <i>Cancer</i> , 2012 , 118, 3984-92	6.4	43
133	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021 , 39, 840-859	2.2	42
132	Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2006 , 6, 383-94	3.5	37
131	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 655-663	9.7	35
130	Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. <i>Cancer</i> , 2015 , 121, 2720-9	6.4	34
129	Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. <i>Supportive Care in Cancer</i> , 2011 , 19, 1625-35	3.9	32
128	Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. <i>Investigational New Drugs</i> , 2010 , 28, 326-33	4.3	32
127	Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines. <i>Investigational New Drugs</i> , 2013 , 31, 567-75	4.3	31
126	Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. <i>Radiology</i> , 2014 , 270, 607-20	20.5	31
125	Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 7080-7	12.9	31
124	Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases. <i>Nature Communications</i> , 2019 , 10, 3256	17.4	30
123	Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma. <i>Annals of Oncology</i> , 2019 , 30, 977-982	10.3	29
122	Head and Neck Tumors: Amide Proton Transfer MRI. <i>Radiology</i> , 2018 , 288, 782-790	20.5	29

121	Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF. <i>Leukemia and Lymphoma</i> , 2001 , 42, 1393-9	1.9	29
120	441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC. <i>Annals of Oncology</i> , 2016 , 27,	10.3	28
119	Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. <i>Oncologist</i> , 2016 , 21, 292-300	5.7	28
118	Nasopharyngeal carcinoma: an evolving paradigm. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 679-695	19.4	28
117	Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. <i>Annals of Oncology</i> , 2020 , 31, 769-779	10.3	27
116	Current and future molecular diagnostics in colorectal cancer and colorectal adenoma. <i>World Journal of Gastroenterology</i> , 2014 , 20, 3847-57	5.6	27
115	Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2520-2520	2.2	27
114	Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study. <i>Clinical Cancer Research</i> , 2018 , 24, 1030-1037	12.9	26
113	Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data. <i>BMC Cancer</i> , 2017 , 17, 8	4.8	25
112	Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. <i>Cancer Letters</i> , 2014 , 343, 24-32	9.9	25
111	Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. <i>Investigational New Drugs</i> , 2011 , 29, 1123-31	4.3	25
110	Nasopharyngeal cancers: which method should be used to measure these irregularly shaped tumors on cross-sectional imaging?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 69, 148-54	4	25
109	Colorectal cancer in Chinese patients: current and emerging treatment options. <i>OncoTargets and Therapy</i> , 2014 , 7, 1817-28	4.4	24
108	Radiation injury of the parotid glands during treatment for head and neck cancer: assessment using dynamic contrast-enhanced MR imaging. <i>Radiation Research</i> , 2011 , 175, 291-6	3.1	24
107	Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts. <i>Cancer Science</i> , 2020 , 111, 536-547	6.9	24
106	Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma--a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor. <i>Oral Oncology</i> , 2007 , 43, 373-8	4.4	23
105	Extranodal extension is a criterion for poor outcome in patients with metastatic nodes from cancer of the nasopharynx. <i>Oral Oncology</i> , 2019 , 88, 124-130	4.4	23
104	Management of hepatocellular carcinoma: beyond sorafenib. <i>Current Oncology Reports</i> , 2012 , 14, 257-66	6.3	22

103	Diffusion-Weighted Imaging of Nasopharyngeal Carcinoma: Can Pretreatment DWI Predict Local Failure Based on Long-Term Outcome?. <i>American Journal of Neuroradiology</i> , 2016 , 37, 1706-12	4.4	22
102	Distinguishing early-stage nasopharyngeal carcinoma from benign hyperplasia using intravoxel incoherent motion diffusion-weighted MRI. <i>European Radiology</i> , 2019 , 29, 5627-5634	8	21
101	Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma. <i>Investigational New Drugs</i> , 2013 , 31, 1399-408	4.3	21
100	Personalizing therapy for colorectal cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 139-44	6.9	21
99	Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). <i>Investigational New Drugs</i> , 2015 , 33, 985-91	4.3	20
98	Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. <i>Investigational New Drugs</i> , 2015 , 33, 942-53	4.3	20
97	Clinical significance of frizzled homolog 3 protein in colorectal cancer patients. <i>PLoS ONE</i> , 2013 , 8, e79481	3.7	19
96	Novel systemic therapeutic for nasopharyngeal carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16 Suppl 1, S63-8	6.4	18
95	Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients. <i>British Journal of Cancer</i> , 2011 , 104, 1000-6	8.7	18
94	Pharmacoproteomics study of cetuximab in nasopharyngeal carcinoma. <i>Journal of Proteome Research</i> , 2006 , 5, 3260-7	5.6	18
93	Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy. <i>Cancer</i> , 2004 , 101, 776-81	6.4	18
92	Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma. <i>Scientific Reports</i> , 2018 , 8, 8010	4.9	18
91	The prognostic significance of tumor vascular invasion and its association with plasma Epstein-Barr virus DNA, tumor volume and metabolic activity in locoregionally advanced nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2008 , 44, 1067-72	4.4	17
90	Prediction of distant metastases from nasopharyngeal carcinoma: Improved diagnostic performance of MRI using nodal volume in N1 and N2 stage disease. <i>Oral Oncology</i> , 2017 , 69, 74-79	4.4	16
89	Radiation-induced spinal glioblastoma multiforme. <i>Acta Oncologica</i> , 2006 , 45, 87-90	3.2	16
88	Investigational drugs for nasopharyngeal carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 677-685	5.9	15
87	Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria. <i>Annals of Oncology</i> , 2017 , 28, 1576-1581	10.3	15
86	Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors. <i>Cancer Science</i> , 2016 , 107, 1477-1483	6.9	15

85	MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018 , 13, S407	8.9	15
84	Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 145-55	3.8	14
83	Isolated tumor cells and circulating CK20 mRNA in pN0 colorectal cancer patients. <i>International Journal of Surgical Pathology</i> , 2008 , 16, 119-26	1.2	14
82	Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression. <i>Biomedicine and Pharmacotherapy</i> , 2005 , 59 Suppl 2, S268-71	7.5	14
81	Abstract P6-13-01: Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2-advanced breast cancer 2016 ,		14
80	Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma. <i>British Journal of Cancer</i> , 2018 , 118, 1051-1055	8.7	13
79	Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 295-300	3.5	13
78	Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 1417-25	3.5	12
77	Clinical trial designs for targeted agents. <i>Hematology/Oncology Clinics of North America</i> , 2002 , 16, 1287-305	3.0	12
76	Abstract CT150: Phase II study of spartalizumab (PDR001) vs chemotherapy (CT) in patients with recurrent/metastatic nasopharyngeal cancer (NPC) 2019 ,		12
75	Staging nodal metastases in nasopharyngeal carcinoma: which method should be used to measure nodal dimension on MRI?. <i>Clinical Radiology</i> , 2018 , 73, 640-646	2.9	11
74	Epstein-Barr Virus-Induced Epigenetic Pathogenesis of Viral-Associated Lymphoepithelioma-Like Carcinomas and Natural Killer/T-Cell Lymphomas. <i>Pathogens</i> , 2018 , 7,	4.5	11
73	Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. <i>Future Oncology</i> , 2018 , 14, 2031-2044	3.6	11
72	Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015 , 11, 160-9	1.9	11
71	Combined modality treatment for locally advanced squamous-cell carcinoma of the oropharynx in a woman with Bloom's syndrome: a case report and review of the literature. <i>Annals of Oncology</i> , 2001 , 12, 1015-7	10.3	11
70	Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 6413-6423	12.9	11
69	Early Detection of Cancer: Evaluation of MR Imaging Grading Systems in Patients with Suspected Nasopharyngeal Carcinoma. <i>American Journal of Neuroradiology</i> , 2020 , 41, 515-521	4.4	10
68	Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. <i>Clinical Colorectal Cancer</i> , 2017 , 16, e73-e88	3.8	10

67	Diffusion-weighted imaging of nasopharyngeal carcinoma to predict distant metastases. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017 , 274, 1045-1051	3.5	10
66	A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) with correlation using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). <i>Journal of Clinical Oncology</i> , 2008 , 26, 6055-6055	2.2	10
65	Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF- κ B activation and immune escape. <i>Nature Communications</i> , 2021 , 12, 4193	17.4	10
64	Pre-treatment amide proton transfer imaging predicts treatment outcome in nasopharyngeal carcinoma. <i>European Radiology</i> , 2020 , 30, 6339-6347	8	9
63	An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 1255-61	5.5	9
62	Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. <i>Cancer</i> , 2013 , 119, 4145-53	6.4	9
61	Adjuvant chemoradiation for gastric cancer: experience in the Chinese population. <i>Clinical Oncology</i> , 2007 , 19, 333-40	2.8	9
60	Amide proton transfer MRI detects early changes in nasopharyngeal carcinoma: providing a potential imaging marker for treatment response. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019 , 276, 505-512	3.5	9
59	Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines. <i>Investigational New Drugs</i> , 2013 , 31, 30-8	4.3	8
58	An update on the safety and efficacy of regorafenib in the treatment of solid cancers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 1607-14	5.5	8
57	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6002-6002	2.2	8
56	Pre-treatment intravoxel incoherent motion diffusion-weighted imaging predicts treatment outcome in nasopharyngeal carcinoma. <i>European Journal of Radiology</i> , 2020 , 129, 109127	4.7	7
55	Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. <i>Oncology Reports</i> , 2008 ,	3.5	7
54	Convolutional neural network for discriminating nasopharyngeal carcinoma and benign hyperplasia on MRI. <i>European Radiology</i> , 2021 , 31, 3856-3863	8	7
53	Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2021 , 113, 105127	4.4	7
52	The emerging data on choice of optimal therapy for locally advanced nasopharyngeal carcinoma. <i>Current Opinion in Oncology</i> , 2020 , 32, 187-195	4.2	6
51	The Effect of Centrifugal Force in Quantification of Colorectal Cancer-Related mRNA in Plasma Using Targeted Sequencing. <i>Frontiers in Genetics</i> , 2018 , 9, 165	4.5	6
50	Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e593-e599	3.8	6

49	Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer. <i>Journal of Oncology</i> , 2009 , 2009, 967920	4.5	6
48	The effect of centrifugation on circulating mRNA quantitation opens up a new scenario in expression profiling from patients with metastatic colorectal cancer. <i>Clinical Biochemistry</i> , 2007 , 40, 1277-84	3.5	6
47	Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2006 , 6, 259	4.8	6
46	Jagged 2 silencing inhibits motility and invasiveness of colorectal cancer cell lines. <i>Oncology Letters</i> , 2016 , 12, 5193-5198	2.6	6
45	Nasopharyngeal carcinoma: relationship between invasion of the prevertebral space and distant metastases. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018 , 275, 497-505	3.5	6
44	Sequencing Analysis of Plasma Epstein-Barr Virus DNA Reveals Nasopharyngeal Carcinoma-Associated Single Nucleotide Variant Profiles. <i>Clinical Chemistry</i> , 2020 , 66, 598-605	5.5	5
43	Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR, HER2 Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6417-6428	12.9	5
42	Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?. <i>Internal Medicine Journal</i> , 2019 , 49, 446-454	1.6	5
41	Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer. <i>Oncologist</i> , 2018 , 23, 1436-1445	5.7	4
40	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiotherapy (CRT).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5511-5511	2.2	4
39	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 1307-1316	4	4
38	Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019 , 15, 225-230	1.9	3
37	500 Triple blockade with LEE011, everolimus, and exemestane in women with ER+/HER2 ⁻ advanced/metastatic breast cancer: results from a Phase Ib clinical trial. <i>European Journal of Cancer</i> , 2014 , 50, 163	7.5	3
36	Advanced technologies for studying circulating tumor cells at the protein level. <i>Expert Review of Proteomics</i> , 2013 , 10, 579-89	4.2	3
35	An unusual cause of superior vena cava obstruction. <i>Thorax</i> , 2006 , 61, 182	7.3	3
34	Efficacy of neoadjuvant docetaxel and cisplatin followed by concurrent cisplatin-radiotherapy in locally advanced nasopharyngeal carcinoma (NPC): A randomized phase II study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 6037-6037	2.2	3
33	Recent Advances in the Development of Biomarkers and Chemoradiotherapeutic Approaches for Nasopharyngeal Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020 , 40, 1-11	7.1	2
32	Personalized cancer therapy coming of age: clinical highlights in 2009 and future directions. <i>Personalized Medicine</i> , 2010 , 7, 121-124	2.2	2

31	A novel application of plasma and cerebrospinal fluid level of epstein barr virus DNA in the diagnosis of leptomeningeal metastasis from nasopharyngeal carcinoma. A case report. <i>Oncology</i> , 2008 , 74, 119-22	3.6	2
30	Case of chlorambucil-induced seizure. <i>Internal Medicine Journal</i> , 2006 , 36, 683-4	1.6	2
29	Abstract 4602: Preclinical evaluation of the AKT inhibitor MK2206 in nasopharyngeal carcinoma cell lines 2012 ,		2
28	Abstract CT076: Multicenter phase II study of nivolumab in previously treated patients with recurrent and metastatic non-keratinizing nasopharyngeal carcinoma - Mayo clinic Phase 2 Consortium P2C-MN026, NCI9742, NCT02339558 2017 ,		2
27	Therapeutic vaccination with modified vaccinia Ankara (MVA) encoding Epstein-Barr virus (EBV) target antigens in EBV+ nasopharyngeal carcinoma (NPC). <i>Journal of Clinical Oncology</i> , 2008 , 26, 3052-3052	2.2	2
26	Long-term treatment outcome of nasopharyngeal carcinoma (NPC) using intensity-modulated radiotherapy (IMRT).. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5582-5582	2.2	2
25	A phase I trial of recombinant modified vaccinia ankara (MVA) vaccine encoding Epstein-Barr virus (EBV) antigens.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2592-2592	2.2	2
24	A phase II study of axitinib in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6031-6031	2.2	2
23	Abstract CT069: Baseline gene expression patterns of CDK4/6 inhibitor-naïve or -refractory HR+, HER2- advanced breast cancer in the phase Ib study of ribociclib plus everolimus plus exemestane 2018 ,		2
22	Development and validation of a risk model integrating plasma Epstein-Barr virus DNA (EBV DNA) level and TNM stage for stratification of nasopharyngeal cancer (NPC) to adjuvant therapy. <i>Annals of Oncology</i> , 2019 , 30, ix97-ix98	10.3	2
21	Dynamic Changes of Post-Radiotherapy Plasma Epstein-Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 2827-2836	12.9	2
20	BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?. <i>Targeted Oncology</i> , 2021 , 16, 227-236	5	2
19	The expanding universe of checkpoint inhibitors for nasopharyngeal cancer. <i>Nature Medicine</i> , 2021 , 27, 1512-1513	50.5	2
18	Update on Anti-EGFR Therapy. <i>Journal of Oncology</i> , 2009 , 2009, 157964	4.5	1
17	Transcriptional profiling of tumor biopsies in oncology trials--a 'window' of opportunity for evaluating new drugs in nasopharyngeal cancer?. <i>Annals of Oncology</i> , 2006 , 17, 1611-3	10.3	1
16	A randomized phase II study of concurrent cisplatin-radiotherapy (RT) with or without neoadjuvant chemotherapy using docetaxel and cisplatin in advanced nasopharyngeal carcinoma (NPC). <i>Journal of Clinical Oncology</i> , 2005 , 23, 5544-5544	2.2	1
15	Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6029-6029	2.2	1
14	Effects of regorafenib therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 697-697	2.2	1

13	The association between serum folate level and toxicity of capecitabine.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3566-3566	2.2	1
12	Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3534-3534	2.2	1
11	Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab + first-line (1L) FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 747-747	2.2	1
10	Clinical outcome of neoadjuvant chemoradiation in locally advanced rectal cancer at a tertiary hospital. <i>Hong Kong Medical Journal</i> , 2016 , 22, 546-55	0.7	1
9	Quantitative T1-MRI of the Head and Neck Discriminates Carcinoma and Benign Hyperplasia in the Nasopharynx. <i>American Journal of Neuroradiology</i> , 2020 , 41, 2339-2344	4.4	1
8	Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status. <i>Clinical Colorectal Cancer</i> , 2021 , 20, e21-e34	3.8	0
7	Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia-Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021 , 17, 388-395	1.9	0
6	Identifying an early indicator of drug efficacy in patients (pts) with metastatic colorectal cancer (mCRC): A prospective evaluation of circulating tumor cells (CTC), 18F-fluorodeoxyglucose positron-emission tomography (PET), and the RECIST criteria.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3582-3582	2.2	
5	Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 566-566	2.2	
4	Regional variation in physicians' awareness, understanding, and use of personalized medicine in the treatment of cancer and perception of patient (pt) education.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 574-574	2.2	
3	Randomized phase II study of erlotinib (ERL) in two different schedules with concomitant modified XELOX in the first-line treatment of metastatic colorectal cancer (mCRC): Correlation with serial serum levels of amphiregulin (AMR) and transforming growth factor receptor-alpha (TGFA).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 425-425	2.2	
2	Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, e14501-e14501	2.2	
1	A joint United Kingdom (UK) and Hong Kong (HK) study to determine prognostic factors for hepatocellular carcinoma (HCC) undergoing curative and palliative treatment.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 181-181	2.2	